Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
NCT04369846Phase 2Completed
- Sponsor
- Xantho Biotechnology
- Start
- May 2020
- Primary completion
- Jan 2025
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing GM-XANTHO with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 7 days and Investigator Global Assessment at 28 days. Started May 2020; status: completed.
02
Drugs
GM-XANTHO
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04369846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369846.